Robeco Institutional Asset Management B.V. Has $3.27 Million Position in Innoviva Inc (INVA)

Robeco Institutional Asset Management B.V. boosted its holdings in Innoviva Inc (NASDAQ:INVA) by 69.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 214,744 shares of the biotechnology company’s stock after acquiring an additional 88,183 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.21% of Innoviva worth $3,271,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Affinity Investment Advisors LLC grew its stake in Innoviva by 14.2% during the second quarter. Affinity Investment Advisors LLC now owns 32,086 shares of the biotechnology company’s stock worth $443,000 after buying an additional 3,988 shares during the last quarter. Aperio Group LLC grew its stake in Innoviva by 13.9% during the second quarter. Aperio Group LLC now owns 37,228 shares of the biotechnology company’s stock worth $514,000 after buying an additional 4,555 shares during the last quarter. Municipal Employees Retirement System of Michigan grew its stake in Innoviva by 16.8% during the second quarter. Municipal Employees Retirement System of Michigan now owns 32,680 shares of the biotechnology company’s stock worth $451,000 after buying an additional 4,690 shares during the last quarter. Aurora Investment Counsel grew its stake in Innoviva by 5.2% during the third quarter. Aurora Investment Counsel now owns 109,100 shares of the biotechnology company’s stock worth $1,663,000 after buying an additional 5,433 shares during the last quarter. Finally, Meritage Portfolio Management grew its stake in Innoviva by 1.9% during the second quarter. Meritage Portfolio Management now owns 296,728 shares of the biotechnology company’s stock worth $4,095,000 after buying an additional 5,457 shares during the last quarter. 74.35% of the stock is currently owned by institutional investors and hedge funds.

Shares of INVA stock opened at $17.06 on Friday. Innoviva Inc has a 1 year low of $12.61 and a 1 year high of $17.99. The company has a market cap of $1.72 billion, a PE ratio of 14.58 and a beta of 2.19.

Innoviva (NASDAQ:INVA) last posted its earnings results on Wednesday, October 31st. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.49 by ($0.06). Innoviva had a negative return on equity of 110.01% and a net margin of 75.67%. The firm had revenue of $61.70 million during the quarter, compared to the consensus estimate of $64.00 million. During the same quarter in the previous year, the company earned $0.21 EPS. The business’s revenue was up 27.0% compared to the same quarter last year. Research analysts anticipate that Innoviva Inc will post 1.91 EPS for the current fiscal year.

Several analysts have weighed in on the stock. BidaskClub raised shares of Innoviva from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 10th. Zacks Investment Research raised shares of Innoviva from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a research note on Wednesday, November 7th. Finally, ValuEngine raised shares of Innoviva from a “sell” rating to a “hold” rating in a research note on Wednesday, October 17th. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $17.00.

ILLEGAL ACTIVITY NOTICE: “Robeco Institutional Asset Management B.V. Has $3.27 Million Position in Innoviva Inc (INVA)” was originally posted by WKRB News and is the property of of WKRB News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.wkrb13.com/2018/11/23/robeco-institutional-asset-management-b-v-has-3-27-million-position-in-innoviva-inc-inva.html.

Innoviva Profile

Innoviva, Inc engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI); ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI); and TRELEGY ELLIPTA (the combination FF/UMEC/VI).

Further Reading: Call Option

Want to see what other hedge funds are holding INVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innoviva Inc (NASDAQ:INVA).

Institutional Ownership by Quarter for Innoviva (NASDAQ:INVA)

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply